Evidence map›Paper›PMID 10880410›Full record

Trial reportCirculation2000

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.

Bezafibrate Infarction Prevention (BIP) study

Abstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 284 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
284citing papers in PubMed, 18 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

284 citing papers in PubMed, 18 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Fibrates for primary prevention of cardiovascular disease events.The Cochrane database of systematic reviews · 2016 · on this map
    Pooled it
  6. Pooled it
  7. Fibrates for secondary prevention of cardiovascular disease and stroke.The Cochrane database of systematic reviews · 2015
    Pooled it
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Guideline
  16. Bezafibrate for primary biliary cirrhosis.The Cochrane database of systematic reviews · 2012
    Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial

224 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Bezafibrate Infarction Prevention (BIP) studyIsraeli Society for Prevention of Heart Attacks, Tel-Hashomer, Israel. behar@post.tau.ac.il

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronary heart disease patients with low high-density lipoprotein cholesterol (HDL-C) levels, high triglyceride levels, or both are at an increased risk of cardiovascular events, but the clinical impact of raising HDL-C or decreasing triglycerides remains to be confirmed. METHODS AND

resultsIn a double-blind trial, 3090 patients with a previous myocardial infarction or stable angina, total cholesterol of 180 to 250 mg/dL, HDL-C < or =45 mg/dL, triglycerides < or =300 mg/dL, and low-density lipoprotein cholesterol < or =180 mg/dL were randomized to receive either 400 mg of bezafibrate per day or a placebo; they were followed for a mean of 6.2 years. The primary end point was fatal or nonfatal myocardial infarction or sudden death. Bezafibrate increased HDL-C by 18% and reduced triglycerides by 21%. The frequency of the primary end point was 13. 6% on bezafibrate versus 15.0% on placebo (P=0.26). After 6.2 years, the reduction in the cumulative probability of the primary end point was 7.3%, (P=0.24). In a post hoc analysis in the subgroup with high baseline triglycerides (> or =200 mg/dL), the reduction in the cumulative probability of the primary end point by bezafibrate was 39.5% (P=0.02). Total and noncardiac mortality rates were similar, and adverse events and cancer were equally distributed.

conclusionsBezafibrate was safe and effective in elevating HDL-C levels and lowering triglycerides. An overall trend in a reduction of the incidence of primary end points was observed. The reduction in the primary end point in patients with high baseline triglycerides (> or =200 mg/dL) requires further confirmation.

Indexed as

AgedApolipoprotein A-IApolipoprotein A-IIApolipoprotein C-IIIApolipoproteins CBezafibrateCholesterol, HDLCoronary DiseaseFemaleFibrinogenFollow-Up StudiesHumansHypolipidemic AgentsLipoprotein LipaseMaleMiddle AgedApolipoprotein A-IApolipoprotein A-IIApolipoprotein C-IIIApolipoproteins CBezafibrateCholesterol, HDLFibrinogenHypolipidemic AgentsLipoprotein LipaseTriglycerides

Identifiers

PMID10880410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.